Kaletra (Lopinavir and Ritonavir) Oral Solution shortage
Possibly permanent — AbbVie, the only company we could find that sells lopinavir and ritonavir oral solutions, has told the FDA it is discontinuing its product as of Oct 6, 2026. The FDA lists this under “To be discontinued”. We could not find another company that sells the same medicine, so talk with your prescriber about a long-term plan before your supply runs out.
Kaletra (lopinavir and ritonavir) oral solution is being permanently discontinued by AbbVie. No other makers list this medicine as available right now.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Kaletra still in shortage? — status as of Oct 6, 2026
Still listed as “To be discontinued” as of Oct 6, 2026. We could not find another company that sells lopinavir and ritonavir oral solutions, so this may become permanent. Talk with your prescriber about a long-term plan before your supply runs out.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Jul 24, 2026Currently in shortage1 of 1 product affected.
-
Jul 24, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Kaletra products are affected — by company
Company: AbbVie Inc. 📞 800-633-9110 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Kaletra Oral Solution, 80 mg/mL; 20 mg/mL | 80 mg/mL; 20 mg/mL | — | Discontinuation of the manufacture of the drug | — |
These rows are company reports to the FDA for Lopinavir and Ritonavir Oral Solution — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Kaletra or its generic? options further down this page.
Why is AbbVie discontinuing Kaletra?
AbbVie, the maker of Kaletra, has reported to the FDA that they are permanently stopping the manufacture of Kaletra oral solution (80 mg/mL lopinavir / 20 mg/mL ritonavir). This is a full discontinuation of that specific liquid form of the medication — meaning AbbVie does not plan to make it again.
It's worth noting that AbbVie did not share a specific public reason why they made this decision — just that the manufacture is being discontinued. This report covers only AbbVie's product; it doesn't speak to what other manufacturers may or may not have available.
Based on the company-reported reason(s) and notes on file with the FDA for Lopinavir and Ritonavir Oral Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Kaletra?
Lopinavir and ritonavir oral solution is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
Both strengths of this liquid — the 80 mg/mL and 20 mg/mL combined oral solution — have no listed source available right now among the companies reporting this shortage. The reason given is that the manufacturer is discontinuing production of the drug. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, and there is no estimated-recovery date to share.
Since this appears to be a lasting change, a conversation with your prescriber is the right next step so you do not run out. Please keep taking your medicine as prescribed in the meantime.
- Do not stop, skip, or change your doses on your own.
- Ask your pharmacy to check their wholesalers and other suppliers, since local stock can differ from this national report.
- Talk with your prescriber or pharmacist soon about your options — for example, a different form of the same medicine or a clinician-chosen alternative that fits your treatment.
- Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.
This is general, manufacturer-reported information and is not personal medical advice.
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Kaletra or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists lopinavir and ritonavir oral solutions is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. These are generic versions of Kaletra — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Other dosage forms of lopinavir and ritonavir
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Kaletra 80 mg/mL; 20 mg/mL | AbbVie | 1 bottle | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Codes & classification for pharmacists and billers
Where does this data come from?
Other antiviral shortages
Kaletra shortage FAQs
Is Kaletra still in shortage?
Which strengths of Kaletra are affected?
Which Kaletra products are affected?
When will Kaletra be available again?
Can I still get Kaletra or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Kaletra?
Still have a question about the Kaletra shortage?
Ask a pharmacist about this shortage →View Lopinavir And Ritonavir Oral Solution on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.